Bionime (TPE:4737) Beneish M-Score: -3.09 (As of Jun. 26, 2026)


TPE:4737 Bionime Corp TPE:4737
65 GF Score
Price NT$57.10
GF Value NT$58.96
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime Beneish M-Score?

Bionime TPE:4737 65 Beneish M-Score is -3.09 as of Jun. 26, 2026. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.96 (Fairly Valued). The stock has 7 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Bionime ranks better than 80.42% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.09 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bionime's Beneish M-Score or its related term are showing as below:

TPE:4737' s Beneish M-Score Range Over the Past 10 Years
Min: -3.09   Med: -2.54   Max: -1.81
Current: -3.09

During the past 13 years, the highest Beneish M-Score of Bionime was -1.81. The lowest was -3.09. And the median was -2.54.


Bionime Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bionime's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Beneish M-Score Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -1.81 -2.77 -2.21 -3.09

Bionime Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -2.43 -2.72 -2.72 -3.09

TPE:4737 vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Bionime's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionime Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionime's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bionime's Beneish M-Score falls into.


TPE:4737
65GF Score
Bionime Corp TPE:4737
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bionime for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7865+0.528 * 1.1637+0.404 * 1.2195+0.892 * 0.9508+0.115 * 0.9718
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8711+4.679 * -0.118344-0.327 * 1.0278
=-3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$541 Mil.
Revenue was 426.963 + 458.499 + 471.685 + 481.441 = NT$1,839 Mil.
Gross Profit was 168.892 + 126.049 + 152.705 + 180.164 = NT$628 Mil.
Total Current Assets was NT$1,561 Mil.
Total Assets was NT$5,704 Mil.
Property, Plant and Equipment(Net PPE) was NT$2,780 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$182 Mil.
Selling, General, & Admin. Expense(SGA) was NT$476 Mil.
Total Current Liabilities was NT$2,078 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,867 Mil.
Net Income was -92.448 + -60.51 + -14.753 + -12.566 = NT$-180 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 66.435 + 142.463 + 133.613 + 152.291 = NT$495 Mil.
Total Receivables was NT$723 Mil.
Revenue was 502.216 + 488.272 + 474.785 + 468.473 = NT$1,934 Mil.
Gross Profit was 182.692 + 178.273 + 205.422 + 201.996 = NT$768 Mil.
Total Current Assets was NT$1,774 Mil.
Total Assets was NT$5,781 Mil.
Property, Plant and Equipment(Net PPE) was NT$2,874 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$183 Mil.
Selling, General, & Admin. Expense(SGA) was NT$575 Mil.
Total Current Liabilities was NT$2,311 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,579 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(540.537 / 1838.588) / (722.82 / 1933.746)
=0.293996 / 0.373793
=0.7865

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(768.383 / 1933.746) / (627.81 / 1838.588)
=0.397355 / 0.341463
=1.1637

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1561.116 + 2780.304) / 5704.4) / (1 - (1774.198 + 2874.383) / 5781.271)
=0.238935 / 0.195924
=1.2195

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1838.588 / 1933.746
=0.9508

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(182.805 / (182.805 + 2874.383)) / (182.278 / (182.278 + 2780.304))
=0.059795 / 0.061527
=0.9718

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(476.3 / 1838.588) / (575.107 / 1933.746)
=0.259057 / 0.297406
=0.8711

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1866.785 + 2078.308) / 5704.4) / ((1579.181 + 2310.998) / 5781.271)
=0.691588 / 0.672893
=1.0278

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-180.277 - 0 - 494.802) / 5704.4
=-0.118344

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bionime has a M-score of -3.09 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.09 mean?
Bionime (TPE:4737) has a Beneish M-Score of -3.09 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bionime and its competitors. According to the industry distribution chart, Bionime ranks #150 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 19.6%.
Is Bionime's Beneish M-Score too high?
Bionime's current Beneish M-Score is -3.09. Based on the distribution chart, Bionime ranks #150 out of 766 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #150 out of 766 companies for Beneish M-Score. This places Bionime in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bionime and its competitors. Bionime's current Beneish M-Score is -3.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.96, compared to a current price of NT$57.10 — trading 3.2% below its estimated fair value. The current Beneish M-Score is -3.09. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bionime (TPE:4737), the current Beneish M-Score is -3.09 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be undervalued. The current stock price of NT$57.10 is trading 3.2% below its estimated GF Value™ of NT$58.96. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Beneish M-Score: -3.09
  • GF Value™: NT$58.96 vs. price of NT$57.10 (3.2% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score

Get the complete analysis for TPE:4737

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$57.10
Price
NT$58.96
GF Value